Search Results

Showing results 1-11 of 88 for 'Cancer treatment'


  • Looking-for-genes-that-drive-cancer-yardena-samuels-thumb
    Looking for the Genes that Drive Cancer

    Prof. Yardena Samuels, who comes to Weizmann from the National Human Genome Research Institute, uses DNA sequencing to identify new genetic mutations involved in melanoma. She has already made progress by identifying a mutation – found in nearly one-fifth of melanoma cases – in a gene that is already targeted by an approved drug.

    /news-media/news-releases/looking-for-the-genes-that-drive-cancer
  • International_Collaboration_Yields_New_Hope_in_the_Fight_Against_Colon_Cancer
  • 2015-05-acwis-enews-header-isolated-thumbnail
  • double-whammy_lev_6f13a2ab-6925-4647-b818-e585f54b7577
    Double Whammy for Triple-Negative Breast Cancer

    Triple-negative breast cancer is particularly hard to treat because, as its name suggests, it lacks three receptors that usually serve as targets for anti-cancer drugs. Now, Prof. Sima Lev has identified a promising new combination therapy that not only inhibits tumor growth and survival, but gets around the problem of drug-induced resistance.

    /news-media/news-releases/double-whammy-for-triple-negative-breast-cancer
  • immortalized-cells-seger-tn
    To Stop Cancer, Block Its Messages

    Cells send a constant stream of messages to their nuclei for making day-to-day decisions. But this rapid, long-distance communication system is vulnerable to mutations that can lead to unstopped, repeated messages – a ""spam attack"" – that promotes cancer. Now, Prof. Rony Seger and his team have identified a molecule that stops cancer cells from getting their ""mail.""

    /news-media/news-releases/to-stop-cancer-block-its-messages
  • 2017-01-acwis-enews-thumbnail
    A Year of Achievements and Advances

    Looking back at 2016 reveals an exceptional year at the Weizmann Institute, one chock-full of major developments from unprecedented insight into our universe to better understanding of our modern world to truly life-changing – and life-saving – breakthroughs in cancer and medical research. Here are some highlights.

    /news-media/feature-stories/a-year-of-achievements-and-advances
  • Targeting_Tumors_A_New_Strategy_for_Prostate_Cancer_Treatment
  • tookad1-tn
    Weizmann Institute Drug, TOOKAD® Soluble, Approved in Mexico for Prostate Cancer Therapy

    Developed by Profs. Yoram Salomon and Avigdor Scherz, the drug TOOKAD<sup>®</sup> Soluble has been approved in Mexico for use in treating prostate cancer. The therapy, which has no side effects, offers men with prostate problems a crucial new option besides surgery or watchful waiting. Late-stage clinical trials have taken place in Europe and continue in the U.S.

    /news-media/news-releases/weizmann-institute-drug-tookad-soluble-approved-in-mexico-for-prostate-cancer-therapy